Pramlintide
Diabetes medication / From Wikipedia, the free encyclopedia
Dear Wikiwand AI, let's keep it short by simply answering these key questions:
Can you list the top facts and stats about Pramlintide?
Summarize this article for a 10 year old
SHOW ALL QUESTIONS
Pramlintide (trade name Symlin) is an injectable amylin analogue drug for diabetes (both type 1 and 2), developed by Amylin Pharmaceuticals (now a wholly owned subsidiary of AstraZeneca).[1] Pramlintide is sold as an acetate salt.
Quick Facts Clinical data, Trade names ...
Clinical data | |
---|---|
Trade names | Symlin |
AHFS/Drugs.com | Monograph |
MedlinePlus | a605031 |
Routes of administration | Subcutaneous |
ATC code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Bioavailability | 30 to 40% |
Protein binding | ~60% |
Metabolism | Renal |
Elimination half-life | ~48 minutes |
Identifiers | |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank |
|
ChemSpider |
|
UNII | |
KEGG |
|
ChEMBL | |
Chemical and physical data | |
Formula | C171H267N51O53S2 |
Molar mass | 3949.44 g·mol−1 |
3D model (JSmol) | |
| |
| |
NY (what is this?) (verify) |
Close